[UK] +44 (0)1304 892398 [US] +19782 899035 admin@trn.net

TRN – The Research Network Ltd. has become a member of the IMIENABLE Consortium effective from January 1st 2015. TRN will work within the ENABLE consortium to progress a novel gram-negative antibiotic programme originating from international academic research.

Andy McElroy, TRN CEO, said ‘We have been working closely with the ENABLE consortium since its inception to assess a novel antibiotic approach which has high potential for direct-action against gram negative pathogens. We are delighted to formally join the ENABLE consortium to develop and validate this programme through to the clinic with leading European academic and industry partners.’